Long-term relative survival from melanoma in Germany 1997-2013.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
19
7
2018
medline:
9
7
2021
entrez:
19
7
2018
Statut:
ppublish
Résumé
Up-to-date melanoma relative survival (RS) estimates and trend analysis facilitate close monitoring of melanoma patients' prognosis. This study aimed to provide recent 5-year and 10-year RS from melanoma, stratified by prognostic factors, and identify latest survival trends. Data from 12 German cancer registries were analysed. We included patients with primary cutaneous malignant melanoma (ICD-10: C43.X) diagnosed in 1997-2013 who were at least 15 years old. Five-year and 10-year RS were estimated by period analysis. For 10-year RS analyses, we excluded patients who were 75 years of age or older. Analyses were stratified by sex, age, histology, tumour stage, and body site. We included 82 901 patients, of whom 51% were women. The median age at diagnosis was 62 years. Five-year and 10-year RS in 2007-2013 were 92.4 and 90.8%, respectively. RS was higher in women. The prognosis worsened with older age and higher stage. In superficial spreading melanoma and lentigo maligna melanoma, RS was high; it was lower in nodular, acral lentiginous and 'other' melanoma. RS was the highest for melanoma on the arms; RS for melanoma on unknown or overlapping sites of the skin was the lowest. Five-year and 10-year RS increased significantly from 2005-2007 and 2008-2010 to 2011-2013, by 3.5 and 3.3 percentage points, respectively. For melanoma of 'other' histology, 5-year and 10-year RS increased significantly. Ten-year RS also increased significantly in men with superficial spreading melanoma and T4 melanoma, and in women with T3 melanoma. Melanoma RS improved, especially in certain subgroups. The reasons for improvements need to be investigated further.
Identifiants
pubmed: 30020195
doi: 10.1097/CMR.0000000000000482
pii: 00008390-202008000-00007
doi:
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
386-395Références
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available at: http://globocan.iarc.fr/Pages/summary_table_site_sel.aspx. [Accessed 22 March 2018]
Association of Population-Based Cancer Registries in Germany. GEKID Atlas, 2016. Available at: http://www.gekid.de/. [Accessed 22 March 2018]
Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, et al. Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol. 2012; 167:606–612
MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol. 2000; 25:471–475
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol. 2014; 15:23–34
Jansen L, Castro FA, Gondos A, Krilaviciute A, Barnes B, Eberle A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer. 2015; 136:2649–2658
International Association of Cancer Registries (IACR), International Agency for Research on Cancer (IARC), European Network of Cancer Registries (ENCR). International rules for multiple primary cancers (ICD-O third edition). 2004, Lyon. Available at: http://www.iacr.com.fr/images/doc/MPrules_july2004.pdf. [Accessed 22 March 2018]
Union for International Cancer Control (UICC). TNM classification of malignant tumours; publications and resources. 2017. Available at: https://www.uicc.org/resources/tnm/publications-resources. [Accessed 22 March 2018]
Brenner H, Hakulinen T. Implications of incomplete registration of deaths on long-term survival estimates from population-based cancer registries. Int J Cancer. 2009; 125:432–437
Henson DE, Ries LA. The relative survival rate. Cancer. 1995; 76:1687–1688
Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. 1959, Bethesda: MD: National Cancer Institute
Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006; 164:689–696
Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996; 78:2004–2010
Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004; 40:2307–2316
Brenner H, Holleczek B. Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificates only. Cancer Epidemiol Biomarkers Prev. 2011; 20:2480–2486
Berrino F, Esteve J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995; 132:1–14
Brenner H, Gefeller O, Hakulinen T, Arndt V. Period and periodh: period analysis of survival data. 2004. Available at: http://www.imbe.med.uni-erlangen.de/cms/software_period.html. [Accessed 22 March 2018]
Crocetti E, Mallone S, Robsahm TE, Gavin A, Agius D, Ardanaz E, et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer. 2015; 51:2179–2190
Hiripi E, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, et al. Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol. 2012; 23:472–479
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER cancer statistics review, 1975–2013. Bethesda, MD: National Cancer Institute, 2016. Available at: https://seer.cancer.gov/archive/csr/1975_2013/. [Accessed 22 March 2018]
Galceran J, Uhry Z, Marcos-Gragera R, Borras J. Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017; 26:S77–S84
Gondos A, Bray F, Hakulinen T, Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol. 2009; 20:564–573
Ellison LF. Differences in cancer survival in Canada by sex. Health Rep. 2016; 27:19–27
Khosrotehrani K, Dasgupta P, Byrom L, Youlden DR, Baade PD, Green AC. Melanoma survival is superior in females across all tumour stages but is influenced by age. Arch Dermatol Res. 2015; 307:731–740
Eriksson H, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, Ingvar C, Lindholm C, et al. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden. J Clin Oncol. 2014; 32:1356–1364
Downing A, Newton-Bishop JA, Forman D. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England: incidence, mortality and survival in relation to stage of disease, 1993–2003. Br J Cancer. 2006; 95:91–95
Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006; 243:693–698; [discussion 698–700]
Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008; 112:1795–1804
De Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008; 19:583–589
Kindem S, Garcias-Ladaria J, Requena C, Guillen C, Oliver V, Nagore E. Survival advantage of women in localized melanoma mainly relies on clinical-pathological differences by sex. A retrospective study of 1,607 patients in Valencia, Spain. Eur J Dermatol. 2015; 25:247–254
Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Holzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011; 131:719–726
Levi F, Randimbison L, La Vecchia C, Te VC, Franceschi S. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer. 1998; 78:315–319
Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Coebergh JW. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res. 2005; 124:89–107
Hunter HL, Dolan OM, McMullen E, Donnelly D, Gavin A. Incidence and survival in patients with cutaneous malignant melanoma: experience in a U.K. population, 1984–2009. Br J Dermatol. 2013; 168:676–678
Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst. 2016; 108:djv294
De Vries E, Houterman S, Janssen-Heijnen ML, Nijsten T, van de Schans SA, Eggermont AM, et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol. 2007; 18:1110–1116
Bergman R, Brückner-Tuderman S, Hercogova J, Bastian BC. LeBoit PE, Burg G, Weedon D, Sarasain A. Nodular melanoma. World Health Organization classification of tumours. Pathology and genetics of skin tumours. 2006, Lyon: IARC Press68–69
Koh HK, Michalik E, Sober AJ, Lew RA, Day CL, Clark W, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol. 1984; 2:994–1001
Cockburn M, Peng D, Key C. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J. Melanoma. SEER survival monograph: cancer survival among adults: US SEER program, 1988–2001, patient and tumor characteristics. 2007, Bethesda, MD: National Cancer Institute, SEER Program93–100
Borghi A, Corazza M, Minghetti S, Masara A, Virgili A. Malignant melanoma in Ferrara, Northern Italy: epidemiologic survey focusing on tumor thickness. G Ital Dermatol Venereol. 2015; 150:655–662
Downing A, Yu XQ, Newton-Bishop J, Forman D. Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003. Int J Cancer. 2008; 123:861–866
Singh P, Kim HJ, Schwartz RA. Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database. Melanoma Res. 2016; 26:395–400
Uprety D, Bista A, Chennamadhavuni A, Niroula A, Jafri SIM, Smith A, et al. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. Melanoma Res. 2017; 28:56–60
Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012; 66:201–211
Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, et al. Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012; 118:5395–5402
Krebsfrueherkennungs-Richtlinien. BAnz AT 31122014 B4. 2014, Germany: Bundesanzeiger. Available at: https://www.g-ba.de/downloads/62-492-950/KFE-RL_2014-07-24.pdf. [Accessed 22 March 2018]
Breitbart EW, Choudhury K, Anders MP, Volkmer B, Greinert R, Katalinic A, et al. Benefits and risks of skin cancer screening. Oncol Res Treat. 2014; 37Suppl 338–47
Katalinic A, Eisemann N, Waldmann A. Skin cancer screening in Germany. Dtsch Arztebl Int. 2015; 112:629–634
Holleczek B, Brenner H. Reduction of population-based cancer survival estimates by trace back of death certificate notifications: an empirical illustration. Eur J Cancer. 2012; 48:797–804
Brenner H, Castro FA, Eberle A, Emrich K, Holleczek B, Katalinic A, et al. Death certificate only proportions should be age adjusted in studies comparing cancer survival across populations and over time. Eur J Cancer. 2016; 52:102–108